Fed. Circ. Finds Galderma Acne Gel Patents Obvious In IP Row

Law360, Los Angeles (December 11, 2013, 4:26 PM EST) -- The Federal Circuit on Wednesday reversed a district court’s decision in a patent infringement suit between Galderma Laboratories LP and Tolmar Inc., finding that the lower court erred in deciding that claims in four patents owned by Galderma and affiliates are not invalid as obvious.

The Hatch-Waxman case is based on Tolmar’s filing of an Abbreviated New Drug Application seeking approval to market a generic version of Differin Gel 0.3%, a topical medication containing 0.3 percent by weight adapalene approved for the treatment of acne. Galderma...
To view the full article, register now.